These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 7446392)

  • 1. Torsades de pointes as a manifestation of mexiletine toxicity.
    Cocco G; Strozzi C; Chu D; Pansini R
    Am Heart J; 1980 Dec; 100(6 Pt 1):878-80. PubMed ID: 7446392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mexiletine: long-term follow-up of a patient with prolonged QT interval and quinidine-induced torsades de pointes.
    Thomas MG; Giles TD
    South Med J; 1985 Feb; 78(2):205-6. PubMed ID: 3919448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intolerance and ineffectiveness of mexiletine in patients with serious ventricular arrhythmias.
    Poole JE; Werner JA; Bardy GH; Graham EL; Pulaski WP; Fahrenbruch CE; Greene HL
    Am Heart J; 1986 Aug; 112(2):322-6. PubMed ID: 3739884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mexiletine in the management of ventricular dysrhythmias.
    Campbell NP; Pantridge JF; Adgey AA
    Eur J Cardiol; 1977 Dec; 6(4):245-58. PubMed ID: 590296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mexiletine for ventricular arrhythmias.
    Podrid PJ; Lown B
    Am J Cardiol; 1981 Apr; 47(4):895-902. PubMed ID: 6782850
    [No Abstract]   [Full Text] [Related]  

  • 6. Drug-induced torsade de pointes.
    Raehl CL; Patel AK; LeRoy M
    Clin Pharm; 1985; 4(6):675-90. PubMed ID: 2416504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mexiletine for recurring ventricular arrhythmias: assessment by long-term electrocardiographic recordings and sequential electrophysiologic studies.
    Flaker GC; Madigan NP; Alpert MA; Moser SA
    Am Heart J; 1984 Sep; 108(3 Pt 1):490-5. PubMed ID: 6475711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mexiletine antagonizes effects of sotalol on QT interval duration and its proarrhythmic effects in a canine model of torsade de pointes.
    Chézalviel-Guilbert F; Davy JM; Poirier JM; Weissenburger J
    J Am Coll Cardiol; 1995 Sep; 26(3):787-92. PubMed ID: 7642874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of mexiletine in ventricular arrhythmias.
    Chaudron JM; Luwaert RJ
    Acta Cardiol; 1985; 40(6):589-98. PubMed ID: 2420104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mexiletine: a new type I antiarrhythmic agent.
    Schrader BJ; Bauman JL
    Drug Intell Clin Pharm; 1986 Apr; 20(4):255-60. PubMed ID: 2421992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mexiletine in refractory ventricular arrhythmias.
    Fenster PE; Kern KB
    Clin Pharmacol Ther; 1983 Dec; 34(6):777-84. PubMed ID: 6641093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic Effect of Dofetilide and Mexiletine on Prevention of Atrial Fibrillation.
    Liu G; Xue X; Gao C; Huang J; Qi D; Zhang Y; Dong JZ; Ma CS; Yan GX
    J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28522677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atypical ventricular tachycardia as a manifestation of disopyramide toxicity.
    Meltzer RS; Robert EW; McMorrow M; Martin RP
    Am J Cardiol; 1978 Dec; 42(6):1049-53. PubMed ID: 727132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparative study of the anti-arrhythmic activity of mexiletine and lidocaine in ventricular hyperkinetic arrhythmias].
    Rolli A; Bonatti V; Finardi A; Favaro L; Botti G
    G Ital Cardiol; 1981; 11(4):468-76. PubMed ID: 6169578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mexiletine for control of drug-resistant ventricular tachycardia: clinical and electrophysiologic results in 44 patients.
    Waspe LE; Waxman HL; Buxton AE; Josephson ME
    Am J Cardiol; 1983 Apr; 51(7):1175-81. PubMed ID: 6340451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mexiletine, a new antiarrhythmic agent, for treatment of premature ventricular complexes.
    Mehta J; Conti CR
    Am J Cardiol; 1982 Feb; 49(2):455-60. PubMed ID: 6174042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of mexiletine in the medium-term treatment of ventricular arrhythmias. A randomized, double-blind, crossover trial against placebo in ambulatory patients.
    Masotti G; Morettini A; Casolo GC; Ieri A; Zipoli A; Serneri GG
    J Int Med Res; 1984; 12(2):73-80. PubMed ID: 6202571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mexiletine for refractory-ventricular arrhythmias: results using serial electrophysiologic testing.
    DiMarco JP; Garan H; Ruskin JN
    Am J Cardiol; 1981 Jan; 47(1):131-8. PubMed ID: 7457398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mexiletine therapy for ventricular tachycardia.
    Maddox RW; Arnold WS
    South Med J; 1985 Apr; 78(4):482-3. PubMed ID: 3983671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
    Lu HR; Yan GX; Gallacher DJ
    J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.